Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P35573: Variant p.Gly1448Arg

Glycogen debranching enzyme
Gene: AGL
Feedback?
Variant information Variant position: help 1448 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glycine (G) to Arginine (R) at position 1448 (G1448R, p.Gly1448Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In GSD3; deficient in ability to bind glycogen; unstable due to enhanced ubiquitination; forms aggresomes upon proteasome impairment. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 1448 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1532 The length of the canonical sequence.
Location on the sequence: help YDNALDNDNYNLAKGFNYHQ G PEWLWPIGYFLRAKLYFSRL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         YDNALDNDNYNLAKGFNYHQGPEWLWPIGYFLRAKLYF-----SRL

                              YDNALDNDNYNLAKGFNYHQGPEWLWPVGYFLRAKLYF---

Rabbit                        YDNALDNDNYNLAKGFNYHQGPEWLWPVGYFLRAKLYF---

Horse                         YDNALDNDNYNLAKGFNYHQGPEWLWPTGYFLRAKLYF---

Baker's yeast                 YNNGEDSDDFATSKGRNYHQGPEWVWLYGYFLRAFHHFHFK
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1532 Glycogen debranching enzyme



Literature citations
A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease.
Cheng A.; Zhang M.; Gentry M.S.; Worby C.A.; Dixon J.E.; Saltiel A.R.;
Genes Dev. 21:2399-2409(2007)
Cited for: UBIQUITINATION; CHARACTERIZATION OF VARIANT GSD3 ARG-1448; INTERACTION WITH NHLRC1; SUBCELLULAR LOCATION; Glycogen storage disease type IIIa: first report of a causative missense mutation (G1448R) of the glycogen debranching enzyme gene found in a homozygous patient.
Okubo M.; Kanda F.; Horinishi A.; Takahashi K.; Okuda S.; Chihara K.; Murase T.;
Hum. Mutat. 14:542-543(1999)
Cited for: VARIANT GSD3 ARG-1448; VARIANT ARG-1115;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.